​

​

​

​

​

Bristol Myers Squibb to create 350 jobs in Dublin with new investment

Pharma giant to increase Dublin employment to more than 1,000

Pharma giant Bristol Myers Squibb is to invest $400 million (¢370 million) to build a sterile drug product facility at its Dublin campus, creating 350 jobs.
The new facility at Cruiserath in Dublin 15, which will be the company’s first European biologics sterile drug product facility, will support the manufacturing of existing medicines in addition to supporting future drugs.

The new roles will bring the total number of staff employed directly by Bristol Myers Squibb at the campus to more than 1,000.

“This is significant news and a proud day at Cruiserath Biologics as this SDP facility strengthens not only our capabilities on campus, but allows us to be agile and responsive to patient needs across the globe.

This investment will expand our capacity for aseptic drug products, reinforce stable production for global supply and accelerate the development and commercialisation of innovative biologic therapies alongside other pipeline medicines,” said Padraig Keane, vice-president, Cruiserath Biologics. “Across our three sites in Ireland we continue to play a critical role in the global production, development, and supply network.”​